C06再生醫療(細胞治療、基因治療、組織工程等)

The company’s businesses are R&D, production and sales of therapeutic drugs for renal diseases. The mission is “Research and develop various solutions against kidney diseases, improve QOL among patients suffering from kidney diseases, and contribute to society”. Flagship programs are (1) a new therapeutic small molecule for autosomal dominant polycystic kidney disease and (2) cell therapy for chronic kidney disease using iPS cell-derived nephron progenitor cells.